Sino Biopharma Unit's Application for Analgesic Accepted in China

Sino Biopharmaceutical (HKG:1177) unit Beijing Tide Pharmaceutical's new drug application for ropivacaine hydrochloride sustained-release solution was accepted by China's National Medical Products Administration. The acceptance is for the drug as a postoperative long-acting analgesic in adults, according to a Friday Hong Kong bourse filing.